Aerie Pharmaceuticals (NASDAQ: AERI) is one of 282 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Aerie Pharmaceuticals to similar companies based on the strength of its valuation, profitability, analyst recommendations, dividends, earnings, institutional ownership and risk.
This table compares Aerie Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aerie Pharmaceuticals Competitors||-5,381.56%||-435.28%||-40.64%|
This is a summary of recent ratings and recommmendations for Aerie Pharmaceuticals and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aerie Pharmaceuticals Competitors||805||3165||11473||230||2.71|
Aerie Pharmaceuticals currently has a consensus price target of $71.85, suggesting a potential upside of 20.35%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 45.01%. Given Aerie Pharmaceuticals’ rivals higher probable upside, analysts clearly believe Aerie Pharmaceuticals has less favorable growth aspects than its rivals.
Insider and Institutional Ownership
49.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 9.4% of Aerie Pharmaceuticals shares are owned by insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Risk & Volatility
Aerie Pharmaceuticals has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Aerie Pharmaceuticals’ rivals have a beta of 1.88, meaning that their average stock price is 88% more volatile than the S&P 500.
Valuation and Earnings
This table compares Aerie Pharmaceuticals and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Aerie Pharmaceuticals||N/A||-$99.05 million||-17.82|
|Aerie Pharmaceuticals Competitors||$286.20 million||$34.74 million||138.93|
Aerie Pharmaceuticals’ rivals have higher revenue and earnings than Aerie Pharmaceuticals. Aerie Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Aerie Pharmaceuticals rivals beat Aerie Pharmaceuticals on 8 of the 12 factors compared.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan). The Company’s product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Its Rhopressa is a once-daily eye drop. Rhopressa inhibits Rho kinase (ROCK), and the norepinephrine transporter (NET), which are both biochemical targets for lowering IOP. Its Roclatan is a once-daily, fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with open-angle glaucoma. The Company is engaged in conducting Phase III clinical trial for Roclatan.
What are top analysts saying about Aerie Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aerie Pharmaceuticals Inc. and related companies.